Prospective Multicentre Validation of a Landmark Machine Learning Model for ICU Mortality in Neurocritical Care (LANDMARK-ICU)
A Prospective Multicentre Observational Study Validating a Landmark-Based Machine Learning Model for Dynamic Prediction of Mortality in Patients Receiving Continuous Intracranial Pressure Monitoring
Mortality prediction in neurocritical care relies on scores computed at admission, which cannot update as the clinical course evolves. We previously developed a landmark-based machine learning model that converts hourly physiological data, including intracranial pressure, into an updating risk of death. The model was developed in a large public database and validated retrospectively in a second, independent one. This prospective multicentre study will test the model in consecutive patients at participating hospitals in Fujian Province, China. Physiological data will be collected as part of routine care. The model will generate risk estimates that are recorded for analysis but not shown to treating clinicians, and no treatment decision will be influenced by the study. The primary analysis will assess discrimination and calibration of the model for death during the intensive care stay. Secondary analyses will compare the model with severity scores in routine use and examine performance by aetiology.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Model development used the Medical Information Mart for Intensive Care IV database and external validation used the eICU Collaborative Research Database. Both analyses were retrospective and are not part of this registration. This registration covers the prospective multicentre validation only. Inclusion requires age 18 years or older, continuous intracranial pressure monitoring for at least 24 hours, and a diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage. The model uses seven hourly physiological channels with observation masks and elapsed-time features. The primary endpoint is death during the intensive care stay; 28-day mortality, length of stay and Glasgow Outcome Scale at 6 months are secondary. The sample size of 100 patients follows the approved protocol, which assumed area under the curve 0.80 with alpha 0.05 and beta 0.20.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
Fujian
-
Fuzhou, Fujian, Cina
- Fujian Provincial Hospital
-
Fuzhou, Fujian, Cina
- First Affiliated Hospital of Fujian Medical University
-
Quanzhou, Fujian, Cina
- Hui'an County Hospital
-
Quanzhou, Fujian, Cina
- Second Affiliated Hospital of Fujian Medical University
-
Quanzhou, Fujian, Cina
- Shishi City Hospital
-
Zhangzhou, Fujian, Cina
- Zhangzhou Municipal Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Adults in intensive care units of participating hospitals who require continuous intracranial pressure monitoring after acute brain injury.
Descrizione
Inclusion Criteria:
- Age 18 years or older
- Continuous intracranial pressure monitoring for at least 24 hours
- Diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage
- Written informed consent from the patient or a legal representative
Exclusion Criteria:
- Incomplete or unusable intracranial pressure recordings
- Loss to follow-up or unavailable outcome information
- Pre-existing severe neurological disease that would confound assessment
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Neurocritical care cohort
Consecutive patients receiving continuous intracranial pressure monitoring, contributing to the risk set at each landmark. |
Observational application of a fixed prediction model to hourly physiological data; no treatment is assigned or withheld. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 24-hour landmark
Lasso di tempo: 24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
Discrimination of the locked landmark model, quantified as the area under the receiver operating characteristic curve, where 0.5 indicates no discrimination and 1.0 perfect discrimination. Death is ascertained from the medical record and the curve is estimated with a 95% confidence interval |
24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 48-hour and 72-hour landmarks
Lasso di tempo: 48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
Same measurement as the primary outcome, estimated separately at the 48-hour and 72-hour landmarks with 95% confidence intervals |
48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
|
Calibration slope (dimensionless) of the landmark model at the 24-, 48- and 72-hour landmarks
Lasso di tempo: 24, 48 and 72 hours after intensive care admission
|
Slope obtained by logistic regression of the observed outcome on the logit of the predicted risk; a value of 1 indicates perfect calibration, below 1 indicates over-fitting and above 1 under-fitting. |
24, 48 and 72 hours after intensive care admission
|
|
Brier score (range 0 to 1) of the landmark model at the 24-, 48- and 72-hour landmarks
Lasso di tempo: 24, 48 and 72 hours after intensive care admission
|
Mean squared difference between predicted risk and observed outcome, where lower values indicate better overall performance. |
24, 48 and 72 hours after intensive care admission
|
|
Difference in area under the receiver operating characteristic curve (range -1 to 1) between the landmark model and the centre-recorded APACHE II score
Lasso di tempo: 24, 48 and 72 hours after intensive care admission
|
Paired difference in discrimination, computed as model area under the curve minus APACHE II area under the curve on the same patients, with 95% confidence interval; negative values indicate the model discriminates worse than APACHE II |
24, 48 and 72 hours after intensive care admission
|
|
Net benefit (dimensionless) of the landmark model from decision-curve analysis at the 24-hour landmark
Lasso di tempo: 24 hours after intensive care admission
|
Net benefit computed across threshold probabilities from 0.05 to 0.50, compared with the strategies of treating all patients and treating none |
24 hours after intensive care admission
|
|
Area under the receiver operating characteristic curve (range 0 to 1) by primary diagnosis at the 24-, 48- and 72-hour landmarks
Lasso di tempo: 24, 48 and 72 hours after intensive care admission
|
Discrimination estimated separately for traumatic brain injury, aneurysmal subarachnoid haemorrhage and intracerebral haemorrhage, reported descriptively because stratum sizes are expected to be small |
24, 48 and 72 hours after intensive care admission
|
|
28-day all-cause mortality, as specified in the approved protocol
Lasso di tempo: 28 days after intensive care admission
|
28 days after intensive care admission
|
|
|
Length of intensive care stay
Lasso di tempo: From intensive care admission to intensive care unit discharge, up to 28 days
|
Duration of intensive care stay in days, right-censored at day 28 for patients still in intensive care |
From intensive care admission to intensive care unit discharge, up to 28 days
|
|
Glasgow Outcome Scale score (range 1 to 5, higher is better) at 6 months
Lasso di tempo: 6 months after intensive care admission
|
Glasgow Outcome Scale, an ordinal scale from 1 (death) to 5 (good recovery), with higher scores indicating better outcome; assessed by telephone or outpatient follow-up |
6 months after intensive care admission
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Han Chen, MD, Fujian Provincial Hospital
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Disturbi cerebrovascolari
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Malattie vascolari
- Malattia cardiovascolare
- Ferite e lesioni
- Processi patologici
- Attributi della malattia
- Emorragia
- Trauma craniocerebrale
- Trauma, sistema nervoso
- Emorragie intracraniche
- Lesioni cerebrali
- Condizioni patologiche, segni e sintomi
- Lesioni cerebrali, traumatiche
- Malattia critica
- Emorragia cerebrale
- Emorragia subaracnoidea
- Ipertensione intracranica
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- FJPH-ICP-01
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
De-identified individual participant data will not be shared publicly because small centre volumes could permit re-identification. The model specification, analysis code and summary results will be published.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .